Seasonally Strong Q2 — Monsoon Dependency and Execution on Seeds Recovery
Rallis enters Q2 FY27 with momentum from a flat underlying Q1 but faces seasonal headwinds in seeds. The Street is cautious, pricing in modest growth. Monsoon quality and seeds turnaround are the pivots.
The Setup: Seasonality vs. Underlying Headwinds
Rallis India enters the September quarter (Q2) — its seasonally stronger period for agri inputs — with mixed momentum. Q1 FY27 delivered headline growth of 31% in PAT, but that was almost entirely a ₹35 Cr one-off provision write-back; underlying profit was flat. The Street is watching whether Q2 can demonstrate real operational traction, not just accounting relief.
The company's Tata-backed agrichemicals portfolio depends heavily on monsoon timing and intensity. Last year, Q2 FY26 saw excessive rains slash domestic crop care revenue by 3%, and the seeds segment cratered 29% due to supply chain bottlenecks. A crucial question: Has supply normalised, and did the 2026 monsoon cooperate?
What to Expect: On-Plan Metrics
~₹900–950 Cr
Q2 FY26 was ₹861 Cr on monsoon stress; 5–10% growth would reflect normal conditions + price
~₹100–110 Cr
Q2 FY26 delivered ₹102 Cr; Street expects flat to marginal growth on tight operational leverage
~17–18%
Historical 17.9% in Q2 FY26; no reason to assume material expansion in a demand-constrained year
A strong print: Revenue in the ₹950–1,000 Cr range with PAT above ₹110 Cr would signal that monsoon conditions held and the domestic crop care portfolio is gaining traction. Export momentum (up 33% last year) maintained into Q2 would add credibility to full-year guidance.
A weak print: Revenue below ₹890 Cr or PAT below ₹95 Cr would replay last year's monsoon-strike narrative. A continued sharp decline in seeds would raise questions about execution on supply and product competitiveness. Margin compression below 16% EBITDA would worry the Street on pricing power.
On Track for Full-Year Guidance?
Rallis has not issued formal FY27 revenue or profit guidance on the Q1 call, so there is no explicit target to measure against. However, management has signalled ambitions for consistent double-digit revenue growth and operating leverage expansion. Q1's flat underlying profitability, despite top-line growth, suggests that margin expansion is not yet materialising. Q2 will be a test: if crop care grows mid-single digits and seeds remain in recovery, the full-year trajectory becomes tight for double-digit bottom-line expansion.
The Street's View
Since Q1: Filing Scan
1 · CFO Transition (Aug 20)
Bhaskar Swaminathan is departing as CFO effective November 4, 2026, due to personal reasons. No successor was named in the original filing. This mid-quarter transition could create near-term execution risk and investor uncertainty, though it comes after results are finalised.
2 · Auditor Rotation (Jul 27)
S R B C & CO LLP has replaced the prior auditor (routine rotation). No material accounting issues were flagged in the transition, but any accounting policy changes should be monitored in the Q2 disclosures.
3 · Board Refreshes (Jul 22, Jun 24)
Two independent directors — Padmini Khare Kaicker and C.V. Natraj — completed their two-term tenure and departed in late July. A third, Mahesh Girdhar, resigned in June due to professional commitments. Board governance is in transition; one new independent director (Velmurugan Ramadass, Seeds Division head) was appointed.
4 · FII Outflows (Sep, Jul)
FII stake fell from 11.55% (Q4 FY26) to 9.12% (Q1 FY27) — a 243 bp decline. SBI Mutual Fund also trimmed its holding, cutting 2% and then an additional 0.1% in July–September. Ownership rotation into promoter/DII is underway, but the FII retreat suggests institutional caution on the agrichemicals outlook.
The Bottom Line: Three Things to Watch on October 22
Rallis heads into Q2 FY27 results as a seasonally stronger quarter fighting last year's monsoon hangover and ongoing seeds weakness. The Street consensus is middle-of-the-road — a 'Hold' on valuation weakness and uncertainty on execution. The preview: expect revenue in the ₹900–950 Cr range (modest growth on normalised monsoon and export contribution) and PAT around ₹100–110 Cr (flat to low single-digit growth) on stable margins. Management will need to convince the Street that seeds is truly recovering and that export momentum is sustainable, not a one-off.
Three pivots for result day: (1) Seed division recovery: Did supply normalise and margins improve, or is the segment still struggling? (2) Export trajectory: Can the 33% export growth in Q2 FY26 be sustained, or was it a spike? (3) Monsoon impact: How did September 2026 monsoon quality affect domestic crop care pricing and volume vs. plan? The October 23 analyst call will unpack these, and management's tone on guidance will determine whether this 32% retreat from all-time highs is overdone or justified.
Informational and educational content only. Not investment advice.